Philip Siberg
Chief Executive Officer
Q2 report 2026 presentation
Philip Siberg, CEO of Senzime, presents the report for Q2 2026 on July 16.
Presentation
Safeguarding patients during anesthesia and recovery
Senzime develops CE and FDA-cleared precision-based patient monitoring solutions. Our products are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime is listed on Nasdaq Main Market (SEZI) and cross traded in the US on the OTCQX list (SNZZF).
Regulatory PR
Interim report Q2 2026: Strong sensor sales and improved margins, despite continued U.S. monitor market headwinds
Regulatory PR
Senzime and Philips Medical Systems enter development and commercialization partnership
Press release
Invitation to presentations of Senzime’s second quarter 2026 report
Financial info Jan - Jun 2026
Strong sensor sales and improved margins, despite continued U.S. monitor market headwinds
Sensor sales continued their strong momentum, driven by expanding utilization of TetraGraph systems in the market.
While U.S. hospital hardware market conditions remained challenging during the second quarter, we have increased our focus on operational fundamentals resulting in improved margins, a further reduction in our cost base, and a significantly strengthened cash flow. Our objective of reaching profitability within Q4 remains firmly on track.
24,671
KSEK, Net sales
48
%, Growth of sensor sales in constant currencies
46
%, Improvement in cash flow
27
%, Improvement in EBITDA
Subscribe
Subscribe to our financial news to receive updates on our latest financial performance, strategic initiatives, and upcoming opportunities.